Loading…
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-235M | $-247M | $-199M | -59.5% | - | - |
| 2024 | $0M | $-206M | $-216M | $-191M | -57.6% | - | - |
| 2023 | $0M | $-167M | $-174M | $-130M | -31.4% | - | - |
| 2022 | $0M | $-114M | $-118M | $-85M | -28.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 115.14 | 174.17 | 232.85 | 259.85 |
| Operating Income | -115.14 | -174.17 | -232.85 | -259.85 |
| EBITDA | -113.67 | -167.39 | -206.07 | -235.43 |
| EBIT | -115.81 | -169.84 | -208.73 | -238.94 |
| Pretax Income | -118.04 | -174 | -215.39 | -246.83 |
| Tax Provision | 0 | 0.29 | 0.41 | 0.47 |
| Net Income | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income Common Stockholders | -118.04 | -174.28 | -215.79 | -247.30 |
| Total Expenses | 115.14 | 174.17 | 232.85 | 259.85 |
| Interest Expense | 2.22 | 4.16 | 6.66 | 7.89 |
| Research And Development | 79.55 | 126.53 | 174.96 | 189.45 |
| Selling General And Administration | 38.77 | 50.55 | 59.81 | 72.18 |
| Normalized EBITDA | -114.06 | -177.40 | -229.43 | -256.55 |
| Normalized Income | -118.43 | -184.27 | -234.25 | -263.98 |
| Basic EPS | -2.26 | -2.99 | -3.24 | -3.07 |
| Diluted EPS | -2.26 | -2.99 | -3.24 | -3.07 |
| Tax Effect Of Unusual Items | 0 | 0.02 | 4.90 | 4.44 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Total Unusual Items | 0.39 | 10.01 | 23.36 | 21.12 |
| Total Unusual Items Excluding Goodwill | 0.39 | 10.01 | 23.36 | 21.12 |
| Net Income From Continuing Operation Net Minority Interest | -118.04 | -174.28 | -215.79 | -247.30 |
| Reconciled Depreciation | 2.15 | 2.45 | 2.65 | 3.50 |
| Net Interest Income | -2.22 | -4.16 | -6.66 | -7.89 |
| Net Income From Continuing And Discontinued Operation | -118.04 | -174.28 | -215.79 | -247.30 |
| Total Operating Income As Reported | -118.31 | -177.08 | -234.77 | -261.63 |
| Diluted Average Shares | 52.21 | 58.21 | 66.57 | 80.56 |
| Basic Average Shares | 52.21 | 58.21 | 66.57 | 80.56 |
| Diluted NI Availto Com Stockholders | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income Including Noncontrolling Interests | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income Continuous Operations | -118.04 | -174.28 | -215.79 | -247.30 |
| Other Income Expense | -0.67 | 4.33 | 24.13 | 20.92 |
| Other Non Operating Income Expenses | -1.06 | -5.68 | 0.77 | -0.20 |
| Special Income Charges | 0 | 0 | 0 | 0 |
| Gain On Sale Of Security | 0.39 | 10.01 | 23.36 | 21.12 |
| Net Non Operating Interest Income Expense | -2.22 | -4.16 | -6.66 | -7.89 |
| Interest Expense Non Operating | 2.22 | 4.16 | 6.66 | 7.89 |
| Other Operating Expenses | -3.17 | -2.91 | -1.92 | -1.77 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Replimune Group, Inc.this co. | REPL | $197M | - | 0.90 | -59.5% | -0.01 |
| OraSure Technologies, Inc. | OSUR | $205M | - | 0.61 | -20.2% | -0.32 |
| Atrium Therapeutics, Inc. | RNA | $202M | - | -3.21 | -37.0% | - |
| OmniAb, Inc. | OABI | $197M | - | 0.74 | -24.3% | -3.48 |
| Lucid Diagnostics Inc. | LUCD | $194M | - |
| -3.11 |
| -530.4% |
| -4.51 |
| Nkarta, Inc. | NKTX | $192M | - | 0.61 | -33.3% | 0.08 |
| Inogen, Inc. | INGN | $191M | - | 0.99 | -11.8% | -9.27 |
| Cartesian Therapeutics, Inc. | RNAC | $190M | - | -1.33 | 103.2% | -0.70 |
| Quantum-Si incorporated | QSI | $187M | - | 0.85 | -46.0% | -0.31 |
| Peer Median | - | - | 0.61 | -28.8% | -0.70 | |